ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03135860
Recruitment Status : Terminated (This was an exploratory open-label study and has met its initial objectives)
First Posted : May 1, 2017
Last Update Posted : September 18, 2017
Sponsor:
Information provided by (Responsible Party):
Bellerophon

Brief Summary:

The objective of this exploratory study is to examine the utility of high resolution computed tomography (HRCT) to measure changes in functional pulmonary imaging parameters as a function of long term iNO administrationusing the device INOpulse for 4 weeks in relation to Patient Reported Outcome (PRO) and exercise tolerance in subjects with WHO Group 3 PH associated with COPD on LTOT.

Changes from baseline to 4 weeks of pulsed iNO and after 2 weeks of withdrawal from pulsed iNO will be evaluated.


Condition or disease Intervention/treatment Phase
COPD Pulmonary Hypertension Chronic Obstructive Pulmonary Disease Drug: Inhaled Nitric Oxide 30mcg/kg IBW/hr Early Phase 1

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Exploratory Single Arm Study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Exploratory Study to Assess the Effect of Pulsed Inhaled Nitric Oxide on Functional Respiratory Imaging Parameters in Subjects With WHO Group 3 Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long Term Oxygen Therapy (LTOT).
Actual Study Start Date : October 2016
Actual Primary Completion Date : August 21, 2017
Actual Study Completion Date : August 21, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Inhaled Nitric Oxide 30mcg/kg/IBW/hr
Inhaled nitric oxide 30 mcg/kg IBW/hr NO will be administered through the InoPulse Device open label for 4 weeks
Drug: Inhaled Nitric Oxide 30mcg/kg IBW/hr
Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
Other Name: iNO, NO,




Primary Outcome Measures :
  1. change in lobar blood volume at total lung capacity with iNO and the change in lobar blood volume with iNO after 4 weeks of treatment with iNO as measured by HRCT. [ Time Frame: After 4 weeks of treatment ]
    The primary endpoint in this exploratory study is the change in lobar blood volume at total lung capacity with iNO and the change in lobar blood volume with iNO after 4 weeks of treatment with iNO as measured by HRCT.


Secondary Outcome Measures :
  1. Blood vessel % and density on lobar level [ Time Frame: after 4 weeks of treatment ]
    are the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Blood vessel % and density on lobar level

  2. • Blood vessel % and density on lobal level compared among patients with emphysema, chronic bronchitis or combined emphysema and chronic bronchitis as assessed by HRCT [ Time Frame: after 4 week of treatment ]
    are the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Blood vessel % and density on lobal level compared among patients with emphysema, chronic bronchitis or combined emphysema and chronic bronchitis as assessed by HRCT

  3. Total lung volume at TLC [ Time Frame: after 4 week of treatment ]
    the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Total lung Volume at TLC

  4. Lobar volumes at TLC [ Time Frame: after 4 weeks of treatment ]
    the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Lobar volumes at TLC

  5. Internal airflow distribution based on lobar expansion [ Time Frame: after 4 weeks of treatment ]
    the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Internal airflow distribution based on lobar expansion

  6. Airway volume down to generation 8-10 at TLC [ Time Frame: After 4 weeks of treatment ]
    the change in lobar blood volume at total lung capacity with iNO and the change in lobar blood volume with iNO in Airway volume down to generation 8-10 at TLC

  7. Computational Fluid Dynamics (CFD)-based resistance on lobar level [ Time Frame: after 4 weeks of treatment ]
    change in lobar blood volume at total lung capacity with iNO and the change in lobar blood volume with iNO in Computational Fluid Dynamics (CFD)-based resistance on lobar level

  8. Ventilation/perfusion (V/Q) matching [ Time Frame: after 4 weeks of treatment ]
    the change in lobar blood volume at total lung capacity with iNO and the change in lobar blood volume with iNO in Ventilation/perfusion (V/Q) matching

  9. Spirometry [ Time Frame: after 4 weeks of treatment ]
    the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Spirometry

  10. Change from baseline 6MWD; Borg CR10 Dyspnea and Leg Fatigue Score ; PRO [ Time Frame: after 4 weeks of treatment two weeks of withdrawal ]
    Change in baseline to 4 weeks of pulsed iNO and after 2 weeks of withdrawal from pulsed iNO in:6MWD; Borg CR10 Dyspnea and Leg Fatigue Score ; PRO

  11. Change from baseline to 4 weeks of treatment and two weeks of withdrawal [ Time Frame: after 4 weeks of treatment two weeks of withdrawal ]
    • Right Ventricular (RV) and Left Ventricular (LV) size and function, PAP as measured by 2D-echocardiogram with Doppler



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- 1. Male or female patient 2. A confirmed diagnosis of COPD by the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria 3. Pulmonary hypertension will be defined as sPAP ≥ 38 mmHg as determined by echocardiogram (not obtained within ± 7 days of an exacerbation) within the past 12 months.

4. Current or former smokers with at least 10 pack-years of tobacco cigarette smoking before study entry 5. Age ≥ 40 years, ≤ 85 years 6. A post-bronchodilatory FEV1/FVC < 0.7 and a FEV1 < 60% predicted (values obtained within 6 months prior to screening can be used unless obtained within ± 7 days of an exacerbation; otherwise, the test must be performed during screening) 7. Receiving LTOT for ≥ 3 months and ≥ 10 hours per day as determined by history 8. Females of childbearing potential must have a negative pre-scan urine pregnancy test 9. Signed informed consent prior to the initiation of any study mandated procedures or Assessments

Exclusion Criteria:

  • 1. Males who have the intention to father a child during the study. 2. A diagnosis of asthma or other non-COPD respiratory disease, in the opinion of the Investigator 3. Lack of patency of nares upon physical examination 4. Experienced during the last month an exacerbation requiring:

    1. start of or increase in systemic oral corticosteroid therapy and/or
    2. hospitalization 5. Left ventricular dysfunction as measured by:
    1. Screening echocardiographic evidence of left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] < 40%), or
    2. Screening echocardiographic evidence of left ventricular diastolic dysfunction >moderate (i.e., > Grade 3), or
    3. Any history of pulmonary capillary wedge pressure (PCWP), left atrial pressure (LAP) or left ventricular end diastolic pressure (LVEDP) > 18 mmHg as measured during cardiac catheterization within the past 6 months unless documented to have resolved by a subsequent cardiac catheterization 6. Renal impairment (i.e., an estimated GFR CKD-EPI < 30 ml/min/1.73 m2) or history of renal failure using the equation:

      Men:

      crs< 0.9 mg/dL: eGFRCKD-EPI = 141 × (crs /0.9)-0.411 × 0.993Age crs≥ 0.9 mg/dL: eGFRCKD-EPI = 141 × (crs /0.9)-1.209 × 0.993Age

      Woman:

      crs< 0.7 mg/dL: eGFRCKD-EPI = 144 × (crs /0.7)-0.329 × 0.993Age crs≥ 0.7 mg/dL: eGFRCKD-EPI = 144 × (crs /0.7)-1.209 × 0.993Age where crs= Normal and elevated serum creatinine Subjects with possible compromised kidney function (i.e., Glomerular Filtration Rate estimated using the Modification of Diet in Renal Disease equation [eGFR CKD-EPI] between 30 and 60 ml/min/1.73 m2) may be enrolled provided the Radiology Department and Principal Investigator review the medical records of subjects with an eGFR CKD-EPI between 30 and 60 ml/min/1.73 m2 in order to confirm the contrast agent can be safely administered to these subjects and approval by both the Radiology Department and Principal Investigator must be obtained before enrolling these subjects.

      7. Known allergy to contrast media. 8. Clinically significant valvular heart disease that may contribute to PH, including mild or greater aortic valvular disease (aortic stenosis or regurgitation) and/or moderate or greater mitral valve disease (mitral stenosis or regurgitation), or status post mitral valve replacement 9. Use within 30 days of screening or current use of approved PH medications such as sildenafil or bosentan (use of Cialis® or Viagra® for erectile dysfunction is permitted) 10. Use of investigational drugs or devices within 30 days prior to enrollment into the study 11. Any underlying medical or psychiatric condition that, in the opinion of the Investigator, makes the subject an unsuitable candidate for the study


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03135860


Locations
Belgium
Antwerp University Hospital
Edegem, Belgium, 2650
Sponsors and Collaborators
Bellerophon
Investigators
Study Chair: Deborah Quinn, MD Bellerophon

Responsible Party: Bellerophon
ClinicalTrials.gov Identifier: NCT03135860     History of Changes
Other Study ID Numbers: PULSE-COPD-007
First Posted: May 1, 2017    Key Record Dates
Last Update Posted: September 18, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Bellerophon:
Inhaled Nitric Oxide
COPD
Chronic Obstructive Pulmonary Disease
Idopathic Pulmonary Fibrosis
Long Term Oxygen Therapy (LTOT)

Additional relevant MeSH terms:
Hypertension
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Respiratory Tract Diseases
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Gasotransmitters
Protective Agents